LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This

NCT06978088 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Small Lymphocytic Lymphoma
CLL/SLL
Chronic Lymphocytic Leukemia

Interventions

DRUG: LP-168
DRUG: Obinutuzumab

Sponsor

Zulfa Omer

Collaborators

[object Object]